Finally, overexpression of CSF1R was able to partially rescue the proliferative capacity of both BPH-1 cells and BPH-derived primary luminal cells treated with sunitinib, as shown by MTT assays (Fig. S3d–3e). Here, CSF1R is linked to benign prostatic hyperplasia.